Current developments in anti-HIV/AIDS gene therapy

Current Opinion in Investigational Drugs

Volumn 10, Issue 2, 2009, Pages 137-149

  Tsygankov, A Y ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular factor; Decoy; Dominant negative; Lentiviral vector; Ribozyme; RNAi

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; COMPLEMENTARY RNA; DOXYCYCLINE; ENFUVIRTIDE; LAMIVUDINE; LENTIVIRUS VECTOR; MAC46 PROTEIN; MIR 32 VECTOR; RETROVIRUS VECTOR; REV PROTEIN; RIBOZYME; SHORT HAIRPIN RNA; SINGLE STRANDED DNA; SIVMAC 251 VECTOR; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; DNA MODIFICATION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; PROTEIN TARGETING; REVIEW; RIBOZYME THERAPY; RNA INTERFERENCE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS INHIBITION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; RNA INTERFERENCE; RNA, CATALYTIC; RNA, SMALL INTERFERING;

EID: 62249171613     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Luque F, Oya R, Macias D, Saniger L: Gene therapy for HIV-1 infection: Are lethal genes a valuable tool? Cell Mol Biol (2005) 51(1):93-101.
2. Dropulic B, June CH: Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum Gene Ther (2006) 17(6):577-588.
3. Morris KV, Rossi JJ: Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum Gene Ther (2006) 17(5):479-486.
4. von Laer D, Hasselmann S, Hasselmann K: Gene therapy for HIV infection: What does it need to make it work? J Gene Med (2006) 8(6):658-667.
5. Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, Sekaly RP, Conway B, Routy JP: Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents (2000) 16(4):429-434.
6. Si-Mohamed A, Kazatchkine MD, Heard I, Goujon C, Prazuck T, Aymard G, Cessot G, Kuo YH, Bernard MC, Diquet B, Malkin JE et al: Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis (2000) 182(1):112-122.
7. Wensing AM, Boucher CA: Worldwide transmission of drug-resistant HIV. AIDS Rev (2003) 5(3):140-155.
8. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I et al: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis (2005) 192(6):958-966.
9. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA (1997) 94(24):13193-13197.
10. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J et al: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 278(5341):1295-1300.
11. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 278(5341):1291-1295.
12. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9(6):727-728.
13. Morris KV, Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther (2006) 13(6):553-558.
14. Giacca M: Gene therapy to induce cellular resistance to HIV-1 infection: Lessons from clinical trials. Adv Pharmacol (2008) 56:297-325.
15. Malim MH, Bohnlein S, Hauber J, Cullen BR: Functional dissection of the HIV-1 Rev trans-activator - derivation of a transdominant repressor of Rev function. Cell (1989) 58(1):205-214.
16. Ranga U, Woffendin C, Verma S, Xu L, June CH, Bishop DK, Nabel GJ: Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA (1998) 95(3):1201-1206.
17. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA et al: Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 16(9):1065-1074.
18. Bahner I, Sumiyoshi T, Kagoda M, Swartout R, Peterson D, Pepper K, Dorey F, Reiser J, Kohn DB: Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol Ther (2007) 15(1):76-85.
19. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D: Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 78(2):568-575.
20. Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, Johnson RP, Villinger F, von Laer D, Schmitz JE: Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther (2008) 15(17):1210-1222.
21. Lunzen J, Glaunsinger T, Stahmer I, Baehr V, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T et al: Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 15(5):1024-1033. • Infusion of autologous T-cells transduced to express a membrane-anchored peptide that inhibited HIV-1 cell fusion was safe and correlated with beneficial effects in patients with advanced-stage AIDS.
22. Luis Abad J, Gonzalez MA, del Real G, Mira E, Manes S, Serrano F, Bernad A: Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther (2003) 8(3):475-484.
23. Lehmann C, Daumer M, Boussaad I, Sing T, Beerenwinkel N, Lengauer T, Schmeisser N, Wyen C, Fatkenheuer G, Kaiser R: Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol (2006) 37(4):300-304.
24. Yung E, Sorin M, Pal A, Craig E, Morozov A, Delattre O, Kappes J, Ott D, Kalpana GV: Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med (2001) 7(8):920-926.
25. 1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis. Biochim Biophys Acta (2003) 1638(3):197-207.
26. 1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV. Gene Ther (2003) 10(26):2153-2156.
27. Cordelier P, Strayer DS: Using gene delivery to protect HIV-susceptible CNS cells: Inhibiting HIV replication in microglia. Virus Res (2006) 118(1-2):87-97.
28. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 113(6):803-809.
29. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 114(1):21-31.
30. Gaddis NC, Chertova E, Sheehy AM, Henderson LE, Malim MH: Comprehensive investigation of the molecular defect in Vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 77(10):5810-5820.
31. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 300(5622):1112.
32. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 424(6944):94-98.
33. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 424(6944):99-103.
34. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 15(2):166-170.
35. Bishop KN, Holmes RK, Malim MH: Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 80(17):8450-8458.
36. Yap MW, Nisole S, Lynch C, Stoye JP: Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA (2004) 101(29):10786-10791.
37. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD: Human tripartite motif 5α domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 79(14):8969-8978.
38. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J: From the cover: Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc Natl Acad Sci USA (2006) 103(14):5514-5519.
39. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature (2004) 427(6977):848-853.
40. SPRY domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J Virol (2005) 79(5):3139-3145.
41. Sawyer SL, Wu LI, Emerman M, Malik HS: Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA (2005) 102(8):2832-2837.
42. Sakuma R, Noser JA, Ohmine S, Ikeda Y: Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G. Gene Ther (2007) 14(2):185-189. • Although expression of APOBEC3G affected HIV-1 replication only transiently and only at low viral doses, APOBEC3G substantially potentiated the antiviral effect of TRIM5α.
43. Anderson J, Akkina R: Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5α (TRIM 5α) in CD34+ cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum Gene Ther (2008) 19(3):217-228.
44. Zhang J, Scadden DT, Crumpacker CS: Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest (2007) 117(2):473-481. •• The cyclin-dependent kinase inhibitor p21 restricted HIV-1 infection independently of its general effect on cell cycling, suggesting that it may be a potential anti-HIV/AIDS gene therapy target.
45. Henderson EE, Tsygankov AY, Merlo JJ, Romano G, Guan M: Altered replication of human immunodeficiency virus type 1 (HIV-1) in T cell lines retrovirally transduced to express Herpesvirus saimiri proteins StpC and/or Tip. Virology (1999) 264(1):125-133.
46. Raymond AD, Hasham MG, Tsygankov AY, Henderson EE: Herpesvirus saimiri-encoded proteins Tip and StpC modulate human immunodeficiency virus type 1 replication in T-cell lines and lymphocytes independently of viral tropism. Virology (2004) 324(1):60-66.
47. Raymond AD, Hasham M, Tsygankov AY, Henderson EE: H. saimiri tyrosine-kinase interacting protein inhibits Tat function: A prototypic strategy for restricting HIV-1-induced cytopathic effects in immune cells. Virology (2006) 352(2):253-267.
48. Raymond AD, Hasham M, Tsygankov AY, Henderson EE: Herpesvirus saimiri terminal membrane proteins modulate HIV-1 replication by altering Nef and Tat functions. Curr HIV Res (2007) 5(1):79-86.
49. Tsygankov AY: Cell transformation by Herpesvirus saimiri. J Cell Physiol (2005) 203(2):305-318.
50. Smirnova EV, Collingwood TS, Bisbal C, Tsygankova OM, Bogush M, Meinkoth JL, Henderson EE, Annan RS, Tsygankov AY: TULA proteins bind to ABCE-1, a host factor of HIV-1 assembly, and inhibit HIV-1 biogenesis in a UBA-dependent fashion. Virology (2008) 372(1):10-23.
51. Feshchenko EA, Smirnova EV, Swaminathan G, Teckchandani AM, Agrawal R, Band H, Zhang X, Annan RS, Carr SA, Tsygankov AY: TULA: An SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin. Oncogene (2004) 23(27):4690-4706.
52. Carpino N, Turner S, Mekala D, Takahashi Y, Zang H, Geiger TL, Doherty P, Ihle JN: Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. Immunity (2004) 20(1):37-46.
53. Lobato MN, Rabbitts TH: Intracellular antibodies as specific reagents for functional ablation: Future therapeutic molecules. Curr Mol Med (2004) 4(5):519-528.
54. Goncalves J, Silva F, Freitas-Vieira A, Santa-Marta M, Malhó R, Yang X, Gabuzda D, Barbas C 3rd: Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem (2002) 277(35):32036-32045.
55. BouHamdan M, Strayer DS, Wei D, Mukhtar M, Duan LX, Hoxie J, Pomerantz RJ: Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther (2001) 8(5):408-418.
56. Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ, Bouhamdan M, Pomerantz RJ, Kari G, Strayer DS: Protecting from R5-tropic HIV: Individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther (2004) 11(22):1627-1637.
57. Swan CH, Bühler B, Steinberger P, Tschan MP, Barbas CF 3rd, Torbett BE: T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther (2006) 13(20):1480-1492.
58. Cao T, Heng BC: Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications. Ann Clin Lab Sci (2005) 35(3):227-229.
59. Hammer D, Wild J, Ludwig C, Asbach B, Notka F, Wagner R: Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo. Hum Gene Ther (2008) 19(6):622-634. • Fusion of vector-expressed transdominant Gag to a sequence that negatively regulates proteasomal degradation increased the stability of chimeric Gag and its anti-HIV inhibitory properties. The in vivo immune response against cells expressing this form of Gag was decreased because of a reduction in the presentation of its antigenic peptides on the cell surface.
60. Balachandran S, Barber GN: PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol (2007) 383:277-301.
61. Bauer S, Pigisch S, Hangel D, Kaufmann A, Hamm S: Recognition of nucleic acid and nucleic acid analogs by toll-like receptors 7, 8 and 9. Immunobiology (2008) 213 (3-4):315-328.
62. Uematsu S, Akira S: Toll-like receptors (TLRs) and their ligands. Handb Exp Pharmacol (2008) 183:1-20.
63. Müller T, Hamm S, Bauer S: TLR9-mediated recognition of DNA. Handb Exp Pharmacol (2008) 183:51-70.
64. Krug A: Nucleic acid recognition receptors in autoimmunity. Handbook Exp Pharmacol (2008) 183:129-151.
65. Zelenay S, Moraes Fontes MF, Fesel C, Demengeot J, Coutinho A: Physiopathology of natural auto-antibodies: The case for regulation. J Autoimmun (2007) 29(4):229-235.
66. Friedman DM, Rupel A, Buyon JP: Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep (2007) 9(2):101-108.
67. Ferraccioli G, Tolusso B: Infections, B cell receptor activation and autoimmunity: Different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev (2007) 7(2):109-113.
68. Waris G, Alam K: Immunogenicity of superoxide radical modified-DNA: Studies on induced antibodies and SLE anti-DNA autoantibodies. Life Sci (2004) 75(22):2633-2642.
69. Khan F, Siddiqui AA, Ali R: Plasmid DNA acquires immunogenicity on exposure to singlet oxygen. Biochemistry (Mosc) (2006) 71(8):871-878.
70. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
71. Elbashir SM, Harborth J, Weber K, Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (2002) 26(2):199-213.
72. Li M, Rossi JJ: Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol (2005) 309:261-272.
73. Ewald PW: Evolution of mutation rate and virulence among human retroviruses. Philos Trans R Soc Lond B Biol Sci (1994) 346(1317):333-341.
74. Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 69(8):5087- 5094.
75. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, Boerwinkle E, Fu YX: Moderate mutation rate in the SARS coronavirus genome and its implications. BMC Evol Biol (2004) 4:21.
76. Mansky LM: In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy. J Virol (2000) 74(20):9525-9531.
77. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, Mous J: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1995) 206(1):527-534.
78. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 246(4934):1155-1158.
79. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS (1991) 5(2):137-144.
80. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 374(6522):569-571.
81. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, Barrish JC, Zahler R, Colonno RJ, Lin PF: Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol (1995) 69(4):2148-2152.
82. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 69(2):701-706.
83. Li M, Li H, Rossi JJ: RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann NY Acad Sci (2006) 1082:172-179. • Human hematopoietic cells were completely protected against HIV-1 infection in vitro by a lentiviral vector encoding a Tat/Rev common exon shRNA, a ribozyme that degrades the CCR5 mRNA and a TAR decoy. The effect of this triple construct was greater than that of single and double constructs.
84. Sabariegos R, Gimenez-Barcons M, Tapia N, Clotet B, Martinez MA: Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol (2006) 80(2):571-577.
85. Huelsmann PM, Rauch P, Allers K, John MJ, Metzner KJ: Inhibition of drug-resistant HIV-1 by RNA interference. Antiviral Res (2006) 69(1):1-8.
86. Akashi H, Miyagishi M, Yokota T, Watanabe T, Hino T, Nishina K, Kohara M, Taira K: Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol Biosyst (2005) 1(5-6):382-390.
87. Jazag A, Kanai F, Ijichi H, Tateishi K, Ikenoue T, Tanaka Y, Ohta M, Imamura J, Guleng B, Asaoka Y, Kawabe T et al: Single small-interfering RNA expression vector for silencing multiple transforming growth factor-β pathway components. Nucleic Acids Res (2005) 33(15):e131.
88. ter Brake O, Konstantinova P, Ceylan M, Berkhout B: Silencing of HIV-1 with RNA interference: A multiple shRNA approach. Mol Ther (2006) 14(6):883-892. •• Multiple shRNAs targeting conserved HIV-1 regions were screened and the shRNAs that demonstrated the greatest inhibition of HIV-1 replication were expressed from a single lentiviral vector. Inhibition of HIV-1 replication was much greater when the shRNAs were expressed in combination compared with expression of single shRNAs.
89. Anderson J, Li MJ, Palmer B, Remling L, Li S, Yam P, Yee JK, Rossi J, Zaia J, Akkina R: Safety and efficacy of a lentiviral vector containing three anti-HIV genes - CCR5 ribozyme, Tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol Ther (2007) 15(6):1182-1188. •• Hematopoietic cells transduced with the triple lentiviral vector described in reference [83] successfully reconstituted human thymic grafts in SCID mice. The gene-modified thymocytes were resistant to HIV-1 challenge.
90. Hayafune M, Miyano-Kurosaki N, Takaku H, Park WS: Silencing of HIV-1 gene expression by siRNAs in transduced cells. Nucleosides Nucleotides Nucleic Acids (2006) 25(7):795-799.
91. Yamamoto T, Miyoshi H, Yamamoto N, Inoue J, Tsunetsugu-Yokota Y: Lentivirus vectors expressing short hairpin RNAs against the U3-overlapping region of HIV nef inhibit HIV replication and infectivity in primary macrophages. Blood (2006) 108(10):3305-3312.
92. Nishitsuji H, Kohara M, Kannagi M, Masuda T: Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol (2006) 80(15):7658-7666. • Targeting of the integrase gene in combination with the U3 region of the attachment site suppressed HIV-1 replication more effectively than Tat-specific shRNA, suggesting that HIV-1 integration may be an effective therapeutic target.
93. Westerhout EM, ter Brake O, Berkhout B: The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 3:57.
94. Konstantinova P, de Vries W, Haasnoot J, ter Brake O, de Haan P, Berkhout B: Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther (2006) 13(19):1403-1413.
95. Pauls E, Senserrich J, Bofill M, Clotet B, Este JA: Induction of interleukins IL-6 and IL-8 by siRNA. Clin Exp Immunol (2007) 147(1):189-196.
96. Gantier MP, Williams BR: The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev (2007) 18(5-6):363-371.
97. Schlee M, Barchet W, Hornung V, Hartmann G: Beyond double-stranded RNA-type I IFN induction by 3pRNA and other viral nucleic acids. Curr Top Microbiol Immunol (2007) 316:207-230.
98. Sen GC, Peters GA: Viral stress-inducible genes. Adv Virus Res (2007) 70:233-263.
99. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 441(7092):537-541.
100. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saib A, Voinnet O: A cellular microRNA mediates antiviral defense in human cells. Science (2005) 308(5721):557-560.
101. Hariharan M, Scaria V, Pillai B, Brahmachari SK: Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun (2005) 337(4):1214-1218.
102. Yeung ML, Bennasser Y, Le SY, Jeang KT: RNA interference and HIV-1. Adv Pharmacol (2007) 55:427-438.
103. Triboulet R, Mari B, Lin YL, Chable-Bessia C, Bennasser Y, Lebrigand K, Cardinaud B, Maurin T, Barbry P, Baillat V, Reynes J et al: Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 315(5818):1579-1582. •• Dicer and Drosha, which are responsible for miRNA processing, inhibited HIV-1 replication. In turn, HIV-1 actively suppressed the expression of the polycistronic miRNA cluster miR-17/92. This suppression was required for efficient viral replication and was dependent on the Tat co-factor PCAF.
104. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, Zhang H: Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 13(10):1241-1247. •• HIV-1 mRNAs, which were enriched in resting CD4+ T-cells compared with activated CD4+ T-cells, were targeted by a cluster of cellular miRNAs (miR-28, -125b, -150, -223 and -382). These miRNAs appear to be involved in HIV-1 latency, and thus, manipulation of cellular miRNAs could be a novel strategy for purging the HIV-1 reservoir.
105. Christensen HS, Daher A, Soye KJ, Frankel LB, Alexander MR, Laine S, Bannwarth S, Ong CL, Chung SW, Campbell SM, Purcell DF, Gatignol A: Small interfering RNAs against the TAR RNA binding protein, TRBP, a Dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J Virol (2007) 81(10):5121-5131.
106. Klase Z, Kale P, Winograd R, Gupta MV, Heydarian M, Berro R, McCaffrey T, Kashanchi F: HIV-1 TAR element is processed by Dicer to yield a viral μ-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol (2007) 8:63.
107. Khan AU: Ribozyme: A clinical tool. Clin Chim Acta (2006) 367(1-2):20-27.
108. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL et al: Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 15(3):251-262.
109. Macpherson JL, Boyd MP, Arndt AJ, Todd AV, Fanning GC, Ely JA, Elliott F, Knop A, Raponi M, Murray J, Gerlach W et al: Long-term survival and concomitant gene expression of ribozymetransduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med (2005) 7(5):552-564.
110. Kaneko H, Suzuki H, Abe T, Miyano-Kurosaki N, Takaku H: Inhibition of HIV-1 replication by vesicular stomatitis virus envelope glycoprotein pseudotyped baculovirus vectortransduced ribozyme in mammalian cells. Biochem Biophys Res Commun (2006) 349(4):1220-1227.
111. Ramezani A, Ma XZ, Ameli M, Arora A, Joshi S: Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes. Front Biosci (2006) 11:2940-2948. • Multimeric ribozymes specific to env and pol and an antisense targeting the packaging signal and gag substantially inhibited HIV-1 replication. A direct comparison suggested that ribozymes were more efficient at inhibiting HIV-1 replication than antisense.
112. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, Hao Q, Zhou C, Bahner I, Kearns K, Brody K et al: A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood (1999) 94(1):368-371.
113. Marquet R, Isel C, Ehresmann C, Ehresmann B: tRNAs as primer of reverse transcriptases. Biochimie (1995) 77(1-2):113-124.
114. Eberhardy SR, Goncalves J, Coelho S, Segal DJ, Berkhout B, Barbas CF 3rd: Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 80(6):2873-2883.
115. Sahu NK, Shilakari G, Nayak A, Kohli DV: Antisense technology: A selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol (2007) 8(5):291-304.
116. Spurgers KB, Sharkey CM, Warfield KL, Bavari S: Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res (2008) 78(1):26-36.
117. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD et al: Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA (2006) 103(46):17372-17377. • Infusion of autologous T-cells expressing a long env-specific antisense RNA was safe and correlated with beneficial effects in patients with advanced AIDS.
118. Hayafune M, Miyano-Kurosaki N, Kusunoki A, Mouri Y, Takaku H: HIV gene therapy using RNA virus systems. Nucleic Acids Symp Ser (Oxf) (2006) 50:79-80.
119. Jakobsen MR, Haasnoot J, Wengel J, Berkhout B, Kjems J: Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology (2007) 4:29.
120. Agarwal S, Nikolai B, Yamaguchi T, Lech P, Somia NV: Construction and use of retroviral vectors encoding the toxic gene barnase. Mol Ther (2006) 14(4):555-563.
121. Turner LS, Tsugankov AY, Henderson EE: Stpc-based gene therapy targeting latent reservoirs of HIV-1. Antiviral Res (2006) 72(3):233-241.
122. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF et al: Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 96(2):467-474.
123. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA et al: Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood (2000) 96(3):785-793.
124. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R et al: A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 5(6):788-797.
125. Effros RB: Telomerase induction in T cells: A cure for aging and disease? Exp Gerontol (2007) 42(5):416-420.
126. Dagarag M, Ng H, Lubong R, Effros RB, Yang OO: Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2003) 77(5):3077-3083.
127. Dagarag M, Evazyan T, Rao N, Effros RB: Genetic manipulation of telomerase in HIV-specific CD8+ T cells: Enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. J Immunol (2004) 173(10):6303-6311.
128. Ragheb JA, Couture L, Mullen C, Ridgway A, Morgan RA: Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon α2, or diphtheria toxin compared with inhibition by transdominant Rev. Hum Gene Ther (1999) 10(1):103-112.
129. Cordelier P, Calarota SA, Pomerantz RJ, Xiaoshan J, Strayer DS: Inhibition of HIV-1 in the central nervous system by IFN-α2 delivered by an SV40 vector. J Interferon Cytokine Res (2003) 23(9):477-488.
130. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H: α Interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol (2006) 80(15):7645-7657.
131. Brule F, Khatissian E, Benani A, Bodeux A, Montagnier L, Piette J, Lauret E, Ravet E: Inhibition of HIV replication: A powerful antiviral strategy by IFN-β gene delivery in CD4+ cells. Biochem Pharmacol (2007) 74(6):898-910.
132. Miyake K, Miyake N, Shimada T: Development of targeted gene transfer into human primary T lymphocytes and macrophages using high-titer recombinant HIV vectors. J Biotechnol (2007) 129(3):532-538.
133. Zubler RH: Ex vivo expansion of hematopoietic stem cells and gene therapy development. Swiss Med Wkly (2006) 136 (49-50):795-799.
134. Santoni de Sio FR, Gritti A, Cascio P, Neri M, Sampaolesi M, Galli C, Luban J, Naldini L: Lentiviral vector gene transfer is limited by the proteasome at post-entry steps in various types of stem cells. Stem Cells (2008) 26(8):2142-2152.
135. von Laer D, Hasselmann S, Hasselmann K: Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol (2006) 238(1):60-77.
136. Weinberger LS, Schaffer DV, Arkin AP: Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol (2003) 77(18):10028-10036.
137. Westerhout EM, Vink M, Haasnoot PC, Das AT, Berkhout B: A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication. Mol Ther (2006) 14(2):268- 275.
138. Gray DA: Insertional mutagenesis: Neoplasia arising from retroviral integration. Cancer Invest (1991) 9(3):295-304.
139. Cornetta K, Morgan RA, Anderson WF: Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther (1991) 2(1):5-14.
140. Van den Driessche T, Collen D, Chuah MK: Biosafety of onco-retroviral vectors. Curr Gene Ther (2003) 3(6):501-515.
141. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA: Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther (2004) 9(1):5-13.
142. Haviernik P, Bunting KD: Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Curr Gene Ther (2004) 4(3):263-276.
143. Yi Y, Hahm SH, Lee KH: Retroviral gene therapy: Safety issues and possible solutions. Curr Gene Ther (2005) 5(1):25-35.
144. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A, Baum C:
145. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R et al: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-419.
146. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD: Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 2(8):E234.
147. Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B, Schmidt M, von Kalle C, Howe S, Thrasher AJ, Aiuti A et al: Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood (2007) 110(6):1770-1778.
148. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C et al: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 24(6):687-696.
149. Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, Zaia JA: Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 11(6):823-842.
150. Christopher ME, Wong JP: Recent developments in delivery of nucleic acid-based antiviral agents. Curr Pharm Des (2006) 12(16):1995-2006.
151. Taylor JA, Vojtech L, Bahner I, Kohn DB, Laer DV, Russell DW, Richard RE: Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication. Mol Ther (2008) 16(1):46-51.
152. Endoh T, Sisido M, Ohtsuki T: Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. Bioconjug Chem (2008) 19(5):1017-1024.